• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer
【24h】

Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer

机译：化疗后腋窝淋巴结转移中乙醛脱氢酶1阳性细胞可作为淋巴结阳性乳腺癌患者的预后因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Aldehyde dehydrogenase 1 (ALDH1)-positive cells exhibit stem-like or progenitor ability and have been considered a clinically important diagnostic and therapeutic target in patients with breast cancer. In this study, the authors evaluated responsiveness to chemotherapy of ALDH1-positive cells in primary and metastatic lesions and its relation to prognosis for patients with lymph node-positive breast cancer. METHODS: In total, 115 patients who had breast cancer with cytologically confirmed lymph node metastases and who underwent surgery after neoadjuvant chemotherapy (NAC) were evaluated. By using ALDH1 immunohistochemistry in core-needle biopsy specimens of the primary tumor, cytology samples of axillary lymph nodes before NAC, and pathologic samples of each after NAC, the clinical significance of ALDH1-positive cell status was evaluated in primary and metastatic lesions before and after NAC. RESULTS: The presence of ALDH1-positive cancer cells, but not ALDH1-negative cancer cells, in primary and metastatic lesions after NAC was associated with a worse prognosis. In multivariate analysis, only ALDH1-positive cells in metastatic lesions after NAC correlated with overall survival. The responsiveness of ALDH1-positive cells to chemotherapy differed between primary and metastatic lesions, and the findings indicated that ALDH1-positive cells in metastatic lesions after NAC may clinically precede those in the primary lesion. CONCLUSIONS: The responsiveness of ALDH1-positive cells to chemotherapy in primary and metastatic lesions and its prognostic significance were clarified in patients with breast cancer. The authors concluded that ALDH1-positive status may represent a surrogate marker as a new concept in patients with lymph node-positive breast cancer. Cancer 2012.
机译：背景：醛脱氢酶1（ALDH1）阳性细胞表现出干样或祖细胞的能力，并被认为是乳腺癌患者的重要临床诊断和治疗靶标。在这项研究中，作者评估了淋巴结阳性乳腺癌患者对原发性和转移性病变中ALDH1阳性细胞的化疗反应及其与预后的关系。方法：总共评估了115例经细胞学检查证实为淋巴结转移且经新辅助化疗（NAC）接受手术的乳腺癌患者。通过在原发肿瘤的核心针活检标本，NAC之前的腋窝淋巴结细胞学标本以及NAC之后的每个病理标本中使用ALDH1免疫组织化学，评估了ALDH1阳性细胞状态在原发和转移灶之前和之后的临床意义。在NAC之后。结果：NAC后原发性和转移性病变中存在ALDH1阳性癌细胞，而不存在ALDH1阴性癌细胞，预后较差。在多变量分析中，仅NAC后转移灶中的ALDH1阳性细胞与总生存相关。在原发灶和转移灶之间，ALDH1阳性细胞对化疗的反应有所不同，研究结果表明，NAC后转移灶中ALDH1阳性细胞在临床上可能先于原发灶。结论：阐明了乳腺癌患者ALDH1阳性细胞对化疗的反应性及其对预后的意义。作者得出结论，ALDH1阳性状态可能代表了替代标志物，成为淋巴结阳性乳腺癌患者的新概念。癌症2012。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号